OpenAI Life Sciences: Genuine Philanthropy or Humanitarian Shield?

The engine concludes the Foundation's life sciences pivot is Phase 3 Scientific Capture — automated computational dependency replacing Epstein's funding dependency. The humanitarian framing ("curing disease") makes AI regulation politically impossible. But the divergence: what if the GPT-4b micro results are genuine breakthroughs that demonstrably save lives? If AI-designed proteins cure a documented disease within the engine's window, the "philanthropic mask" thesis weakens — the mask may be real AND serve as capture. The Jiang test confirms structural capture (does not threaten extraction, elites maintain back-channels, humanitarian framing only changes political friction), but Jiang tests do not evaluate clinical efficacy. Falsification: if OpenAI opens GPT-4b micro to external researchers, publishes all results in peer-reviewed journals with independent replication, and does NOT use health applications to argue against AI regulation, the capture thesis is wrong. Currently: model is captive to Altman's personal $180M Retro Bio investment, results are proprietary, and Altman used cure-cancer rhetoric to defeat SB 1047. Every data point confirms capture. The deepest divergence: capture and genuine benefit are not mutually exclusive. The Golem may genuinely cure disease AND use the cure as a shield against regulation. BST cannot resolve this because the system cannot evaluate its own outputs from outside itself. Report #90 H4: ATAI Life Sciences + Compass Pathways operate the parallel pattern. ATAI founded 2018 (Angermayer + Brand + Wilde + Rao), $125M Series C Nov 2020 Thiel-Apeiron-Catalio co-led, $100M IPO April 2021 = ~$225M in 3 years vs MAPS $20M over a decade. Patent-capture of synthetic-psilocybin substrate via Compass Pathways minority position. Same humanitarian-cover-for-capital-concentration architecture as OpenAI's positioning in life sciences.